Validation of dried blood spot sampling in therapeutic drug monitoring of nilotinib
Completed
- Conditions
- 10024324Chronic Myelogenous LeukemiaCancer of white blood cells
- Registration Number
- NL-OMON37855
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Patients with CML who are treated with nilotinib.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Difference between specimens across blood sampling methods, and between<br /><br>duplicate specimens for the same blood sampling method will be determined.</p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>